The altered metabolic pathways of diffuse large B-cell lymphoma not otherwise specified

Leuk Lymphoma. 2023 Nov-Dec;64(11):1771-1781. doi: 10.1080/10428194.2023.2234523. Epub 2023 Jul 18.

Abstract

Altered metabolic fingerprints of Diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS) may offer novel opportunities to identify new biomarkers and improve the understanding of its pathogenesis. This study aimed to investigate the modified metabolic pathways in extranodal, germinal center B-cell (GCB) and non-GCB DLBCL NOS from the head and neck. Formalin-fixed paraffin-embedded (FFPE) tissues from eleven DLBCL NOS classified according to Hans' algorithm using immunohistochemistry, and five normal lymphoid tissues (LT) were analyzed by high-performance liquid chromatography-mass spectrometry-based untargeted metabolomics. Partial Least Squares Discriminant Analysis showed that GCB and non-GCB DLBCL NOS have a distinct metabolomics profile, being the former more similar to normal lymphoid tissues. Metabolite pathway enrichment analysis indicated the following altered pathways: arachidonic acid, tyrosine, xenobiotics, vitamin E metabolism, and vitamin A. Our findings support that GCB and non-GCB DLBCL NOS has a distinct metabolomic profile, in which GCB possibly shares more metabolic similarities with LT than non-GCB DLBCL NOS.

Keywords: Non-Hodgkin l-ymphoma; diffuse large B-cell lymphoma; metabolic pathways; metabolomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / metabolism
  • Biomarkers, Tumor* / metabolism
  • Germinal Center / metabolism
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Metabolic Networks and Pathways
  • Prognosis

Substances

  • Biomarkers, Tumor